SUBSCRIBE
SUBSCRIBE
News   Deals

Icahn Says Biogen Idec, Inc. (Massachusetts) Should Weigh Splitting in Two

May 12, 2009 | 
1 min read
Bookmark and Share

Reuters -- Billionaire investor Carl Icahn wants the board of Biogen Idec Inc to consider splitting the biotechnology company into one firm focused on neurology and another focused on cancer.

Mergers & acquisitions
Biogen
MORE ON THIS TOPIC
Neurology, philosophy: connections, the development of thought and reflection, the infinite possibilities of the brain and mind. Creativity stock photo
Mergers & acquisitions
Sanofi Buys Vigil for $470M Upfront, Reigniting a Battered Alzheimer’s Target
May 22, 2025
 · 
4 min read
 · 
Annalee Armstrong
Podcast
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
May 21, 2025
 · 
2 min read
 · 
Heather McKenzie
Big fish eats small, takeover of the company. Art collage.
Mergers & acquisitions
Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan
May 19, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of two arrows merging into one
Mergers & acquisitions
BioMarin Expands Enzyme Expertise With $270M Inozyme Buy
May 16, 2025
 · 
2 min read
 · 
Tristan Manalac